G17DT Immunogen
- Generic Name
- G17DT Immunogen
- Drug Type
- Biotech
Overview
G17DT Immunogen is a vaccine that neutralizes gastrin-17, a hormone required for the growth of a number of cancers of the gastrointestinal tract. It is in phase III trials for advanced pancreatic cancer as a monotherapy and in combination with gemcitabine. It is also in a phase II/III trial for advanced stomach cancer in combination with 5-fluorouracil and cisplatin and in a late phase II trial for advanced colorectal cancer in combination with irinotecan.
Background
G17DT Immunogen is a vaccine that neutralizes gastrin-17, a hormone required for the growth of a number of cancers of the gastrointestinal tract. It is in phase III trials for advanced pancreatic cancer as a monotherapy and in combination with gemcitabine. It is also in a phase II/III trial for advanced stomach cancer in combination with 5-fluorouracil and cisplatin and in a late phase II trial for advanced colorectal cancer in combination with irinotecan.
Indication
Intended for the treatment of various forms of cancer.
Associated Conditions
No associated conditions information available.
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.